Summary: OGT launched a new next-generation sequencing (NGS) tool designed to identify key fusion genes associated with acute myeloid leukemia (AML). This new panel allows for the detection of over 30 disease-associated fusions in a single assay.

Takeaways:

  1. The SureSeq Myeloid Fusion Panel utilizes a partner-gene agnostic approach, enabling it to identify a wide array of fusions, including multiple partners and novel, rare fusions, which enhances the ability to classify diverse AML samples accurately.
  2. This panel integrates with OGT’s Universal NGS Complete Workflow Solution and the company’s data analysis software. This integration minimizes the need for extensive bioinformatics expertise and reduces hands-on time, facilitating easier and faster analysis.
  3. The introduction of the SureSeq Myeloid Fusion Panel broadens OGT’s portfolio and aims to reinforce the company’s commitment to enhancing cancer research and diagnostics.

OGT, a provider of genomic research and diagnostic solutions, announced the launch of the RNA-based SureSeq Myeloid Fusion Panel, a new next-generation sequencing (NGS) tool for identifying key fusion genes implicated in acute myeloid leukaemia (AML). 

The New SureSeq Myeloid Fusion Panel

Designed in collaboration with leading myeloid cancer experts, the SureSeq Myeloid Fusion Panel aims to ensure that results meet the latest clinical research recommendations by efficiently identifying over 30 key disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay. By utilizing a partner-gene agnostic approach, fusions with multiple partners as well as novel and rare fusions can be identified, expanding the ability to classify samples, according to OGT.

Compatibility with NGS Solution

This panel is fully compatible with OGT’s existing end-to-end Universal NGS Complete Workflow Solution, and complimentary data analysis software, Interpret, to minimize hands-on time and provide easy analysis without the need for additional bioinformatics resources.

“We’re thrilled to be announcing the launch of the SureSeq Myeloid Fusion Panel, the latest addition to OGT’s growing NGS haemato-oncology portfolio” says Adrian Smith, CEO of OGT, “Our substantial experience with genetic technologies, combined with insights from leading myeloid cancer experts, has allowed us to develop a valuable tool for myeloid research, supported by a highly efficient workflow. This will enable users to confidently and rapidly detect the most relevant fusion genes in a single assay.”

Further reading: OGT Gets IVDR-Certification for FISH Probes

The launch of the SureSeq Myeloid Fusion Panel expands OGT’s portfolio to offer more NGS solutions for haematological malignancies and solid tumour cancer research than ever before. 

Featured image: SureSeq Myeloid Fusion Panel. Photo: OGT